TibaRay, a Stanford spinout developing next-generation accelerator technology for FLASH radiotherapy, has launched a Regulation CF campaign on Wefunder, opening the company to individual investors for the first time. The campaign seeks to fund further development of the company's proprietary Galactica linear accelerator, which is designed to deliver radiation doses hundreds of times faster than conventional systems, potentially reducing harm to healthy tissue while maintaining tumor control.
The company's technology is grounded in decades of research in accelerator and medical physics, with over $27 million invested to date, including more than $14 million in non-dilutive federal research grants. TibaRay holds an intellectual property portfolio of more than 20 issued and pending patents related to next-generation radiotherapy systems. Its Galactica accelerator has already been integrated into Leo Cancer Care's upright radiotherapy system, marking its first commercial application.
FLASH radiotherapy, which delivers ultra-high dose rates, has shown promise in preclinical studies for sparing healthy tissue while effectively targeting tumors. However, enabling this treatment requires fundamentally new accelerator technology, which TibaRay is developing. The company's long-term goal is to deploy the PHASER radiotherapy system, designed to enable ultrafast treatment delivery. In the near term, TibaRay generates revenue by commercializing its accelerator technology across medical and adjacent markets, including imaging, security scanning, and non-destructive testing.
Individual investors can learn more about the technology, partnerships, and development plans on the TibaRay campaign page on Wefunder. The campaign allows investors to participate in the next phase of development, as the company works toward transforming cancer care.
This announcement is significant because it opens a pathway for public participation in a technology that could fundamentally change radiotherapy. If successful, TibaRay's FLASH technology could improve outcomes for cancer patients by reducing side effects and enabling more precise treatment. The company's phased commercialization strategy, which includes immediate revenue streams from adjacent markets, may reduce risk while advancing toward its primary goal. For more details, refer to the original release on NewMediaWire.
